Physician profile
Lauren E Maxham
NPI 1326347154
$1,362.04
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $643 · 2020: $261 · 2021: $181 · 2022: $278.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $278.93 | 2019-2022 | |
| Pfizer INC. | $272.96 | 2019-2021 | |
| Inari Medical, INC. | $265.33 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.19 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.67 | 2019-2020 | |
| Glaxosmithkline, LLC. | $59.57 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $41.83 | 2019-2021 | |
| Ascensia Diabetes Care US INC. | $39.80 | 2019 | |
| Amgen INC. | $34.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $27.23 | 2019 | |
| Janssen Pharmaceuticals, INC | $26.02 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $23.73 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $13.44 | 2021 | |
| Pulmonx Corporation | $13.26 | 2019 | |
| Circassia INC. | $12.08 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Maxham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.